COMPARATIVE EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
Journal of Biosciences and Innovations · 30.06.2026 · 3 (01) · 31-48
DOI: 10.64037/jbi.01.35 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biosciences and Innovations, online erschienen am 30.06.2026. Verfasst von Naila Nadeem. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
TNF-alpha, IL-17, IL-23 and IL-12/23 are biologic therapies which have revolutionized the treatment of moderate-to-severe psoriasis, and it remains not clear whether they have the same efficacy and safety because of the lack of head-to-head studies. Our systematic review and network meta-analysis have summarized 147 randomized controlled trials and 23 real-world studies (58,412 patients) which have compared 19 treatments. To come up with such model, a meta-regression of dose response parameters (E o C, ED 0, Hill coefficient n, onset rate k, decay half-life ) were founded on a meta-analysis of model-driven longitudinal analysis. Results were PASI 75/90/100 results, serious adverse events, and composite risk scores.: IL-23 inhibitors (risankizumab, guselkumab) had the best SUCRA scores in PASI 90 at week 48 (0.964 and 0.931), almost complete response maintenance, and the best safety profiles. The IL-17 inhibitors had a fast activation and an intermediate decay .. In the past, biologic exposure and rapid attenuation of response has been demonstrated to be a cause of high attenuation of TNF-alpha blockers. The traditional ones were the lowest ranked systemics. None of the major network inconsistency was detected. The IL-23 inhibitors have shown superior and sustained effects and safety indicating the most appropriate initial biologic therapy in psoriasis treatment in the long run. Il-17 inhibitors will be needed in case there is a necessity to get a fast response. The results of these evidences can be applied in the clinical decision making process during pharmacotherapy of psoriasis.
Zitieren
APA
Nadeem, N. (2026). COMPARATIVE EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS. Journal of Biosciences and Innovations, 3(01), 31-48. https://doi.org/10.64037/jbi.01.35
Vancouver
Nadeem N. COMPARATIVE EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS. Journal of Biosciences and Innovations. 2026;3(01):31-48. doi:10.64037/jbi.01.35
BibTeX
@article{Nadeem2026,
author = {Nadeem, Naila},
title = {COMPARATIVE EFFECTIVENESS OF BIOLOGIC THERAPIES IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS},
journal = {Journal of Biosciences and Innovations},
year = {2026},
volume = {3},
number = {01},
pages = {31--48},
doi = {10.64037/jbi.01.35}
}
EUVIMED